High Prevalence of Chronic Viral Hepatitis and Liver Fibrosis Among Mongols in Southern California.
Adolescent
Adult
Aged
Antibodies, Viral
/ blood
Asian People
Cross-Sectional Studies
Female
Genotype
Hepatitis B virus
/ genetics
Hepatitis B, Chronic
/ complications
Hepatitis C, Chronic
/ complications
Hepatitis D, Chronic
/ complications
Humans
Liver Cirrhosis
/ epidemiology
Male
Middle Aged
Mongolia
RNA, Viral
/ blood
Young Adult
Cirrhosis
Fatty liver
Hepatitis B
Hepatitis C
Hepatitis delta
Journal
Digestive diseases and sciences
ISSN: 1573-2568
Titre abrégé: Dig Dis Sci
Pays: United States
ID NLM: 7902782
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
received:
26
05
2020
accepted:
18
07
2020
pubmed:
10
8
2020
medline:
23
9
2021
entrez:
10
8
2020
Statut:
ppublish
Résumé
Mongolia is a highly endemic region for chronic hepatitis B (HBV), hepatitis delta (HDV), and hepatitis C (HCV) infections. Aim of this study was to comprehensively characterize chronic viral hepatitis among Mongols living in Southern California. Three screening events were conducted between August and November 2018, with 528 adult Mongols tested for HBV and HCV. HBsAg (+) individuals (CHB) underwent additional testing for HDV RNA and anti-HDV. Liver tests, platelet count, and FibroScan™ were performed on CHB and chronic HCV (CHC) individuals. Fifty-one out of 534 were HBsAg reactive (9.7%), and all were foreign-born. Mean age of CHB individuals was 37.8 (range 18-69) years. Forty-six out of 51 were HBeAg (-). HBV genotypes were exclusively D2 or A1. Twenty-one out of 51 (41.2%) were anti-HDV (+) and 17/51 (33.3%) were HDV RNA (+). HDV RNA (+) individuals had significantly higher ALT, fibrosis-4 score, and liver stiffness compared to HDV RNA (-) individuals. Incidence of advanced fibrosis was higher in HDV RNA (+) individuals (57% vs. 13%, p = 0.013). Forty-eight (9.1%) individuals were anti-HCV (+) and 19 (3.6%) were HCV RNA (+). Mean age of CHC individuals was 40.2 (range 28-71) years. Prevalence of anti-HCV (+) was higher among those born between 1945 and 1965 versus those born after 1965 (18.8% vs. 7.9%, p = 0.025). Genotype 1b was predominant. Incidence of cirrhosis was 7% among all participants. Mongols living in the USA are at high risk for CHB and CHC infections. One-third of CHB individuals had CHD superinfection with advanced fibrosis. Universal screening for viral hepatitis in Mongols in the USA is mandatory.
Sections du résumé
BACKGROUND
Mongolia is a highly endemic region for chronic hepatitis B (HBV), hepatitis delta (HDV), and hepatitis C (HCV) infections. Aim of this study was to comprehensively characterize chronic viral hepatitis among Mongols living in Southern California.
METHODS
Three screening events were conducted between August and November 2018, with 528 adult Mongols tested for HBV and HCV. HBsAg (+) individuals (CHB) underwent additional testing for HDV RNA and anti-HDV. Liver tests, platelet count, and FibroScan™ were performed on CHB and chronic HCV (CHC) individuals.
RESULTS
Fifty-one out of 534 were HBsAg reactive (9.7%), and all were foreign-born. Mean age of CHB individuals was 37.8 (range 18-69) years. Forty-six out of 51 were HBeAg (-). HBV genotypes were exclusively D2 or A1. Twenty-one out of 51 (41.2%) were anti-HDV (+) and 17/51 (33.3%) were HDV RNA (+). HDV RNA (+) individuals had significantly higher ALT, fibrosis-4 score, and liver stiffness compared to HDV RNA (-) individuals. Incidence of advanced fibrosis was higher in HDV RNA (+) individuals (57% vs. 13%, p = 0.013). Forty-eight (9.1%) individuals were anti-HCV (+) and 19 (3.6%) were HCV RNA (+). Mean age of CHC individuals was 40.2 (range 28-71) years. Prevalence of anti-HCV (+) was higher among those born between 1945 and 1965 versus those born after 1965 (18.8% vs. 7.9%, p = 0.025). Genotype 1b was predominant. Incidence of cirrhosis was 7% among all participants.
CONCLUSIONS
Mongols living in the USA are at high risk for CHB and CHC infections. One-third of CHB individuals had CHD superinfection with advanced fibrosis. Universal screening for viral hepatitis in Mongols in the USA is mandatory.
Identifiants
pubmed: 32770488
doi: 10.1007/s10620-020-06499-6
pii: 10.1007/s10620-020-06499-6
pmc: PMC7868472
mid: NIHMS1619042
doi:
Substances chimiques
Antibodies, Viral
0
RNA, Viral
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
2833-2839Subventions
Organisme : NIAID NIH HHS
ID : R21 AI139954
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2020. Springer Science+Business Media, LLC, part of Springer Nature.
Références
Lancet. 2004 Jan 10;363(9403):157-63
pubmed: 14726171
J Hepatol. 2014 Nov;61(1 Suppl):S45-57
pubmed: 25086286
Arch Virol. 2005 Dec;150(12):2513-28
pubmed: 16012782
J Hepatol. 2015 Sep;63(3):586-92
pubmed: 25962883
J Viral Hepat. 2017 Apr;24(4):320-329
pubmed: 27917600
J Viral Hepat. 2013 Aug;20(8):575-81
pubmed: 23808996
Am J Epidemiol. 1988 Jun;127(6):1250-60
pubmed: 3369423
Ann Intern Med. 1986 Jul;105(1):108-14
pubmed: 3717781
Aliment Pharmacol Ther. 2013 May;37(10):921-36
pubmed: 23557103
J Gastroenterol Hepatol. 2013 Aug;28 Suppl 1:7-10
pubmed: 23855289
J Viral Hepat. 2007 Sep;14(9):667-74
pubmed: 17697020
Hepatology. 2017 Dec;66(6):1739-1749
pubmed: 27880976
Hepatology. 2012 Aug;56(2):422-33
pubmed: 22105832
Hepatology. 2017 Mar;65(3):828-835
pubmed: 28035771
J Med Virol. 2007 Aug;79(8):1064-74
pubmed: 17596839
Sci Rep. 2018 May 23;8(1):8047
pubmed: 29795302
West J Med. 1988 Mar;148(3):307-9
pubmed: 3363963
Lancet. 2011 Jul 2;378(9785):73-85
pubmed: 21511329
J Med Virol. 2006 May;78(5):542-50
pubmed: 16555292
Eur J Cancer Prev. 2011 Jan;20(1):33-9
pubmed: 21166097
Hepatol Res. 2011 Oct;41(10):936-45
pubmed: 21883742
J Epidemiol. 2007 May;17(3):69-75
pubmed: 17545693
J Med Virol. 2005 Dec;77(4):491-9
pubmed: 16254981
World J Hepatol. 2015 Mar 27;7(3):289-303
pubmed: 25848459
Obesity (Silver Spring). 2016 Oct;24(10):2194-201
pubmed: 27580924
Clin Gastroenterol Hepatol. 2015 Jan;13(1):183-92
pubmed: 25010003
World J Gastroenterol. 2014 Aug 7;20(29):9633-52
pubmed: 25110404
J Med Virol. 2005 Jul;76(3):333-40
pubmed: 15902700
J Gastroenterol Hepatol. 2013 Sep;28(9):1521-5
pubmed: 23574043
J Clin Gastroenterol. 2016 Aug;50(7):602-7
pubmed: 26890328
Liver Int. 2007 Jun;27(5):607-11
pubmed: 17498244
Dig Dis Sci. 2015 Dec;60(12):3513-24
pubmed: 26112990
J Infect Dis. 2018 May 25;217(12):1902-1906
pubmed: 29800369
Virus Res. 2018 May 2;250:114-117
pubmed: 29596839
Prev Chronic Dis. 2019 Jan 24;16:E08
pubmed: 30676936
Hepatology. 2018 Apr;67(4):1560-1599
pubmed: 29405329
J Viral Hepat. 2017 Sep;24(9):759-767
pubmed: 28211256
Mol Biol Evol. 2016 Jul;33(7):1870-4
pubmed: 27004904
J Viral Hepat. 2018 Jul;25(7):842-852
pubmed: 29406564